Eli Lilly Company and Bristol-Myers Squibb have announced the stopping of enrollment in one of their two global Phase 3 studies of necitumumab, an investigational treatment for first-line advanced non-small cell lung cancer. ---Subscribe to MedNous to access this article--- Company News
